

Critical Care

Katie M. Szyman
Corporate Vice President,
Critical Care



Building Future Growth with Innovation

**Critical Care
Products Benefit
Millions of
Patients per Year**



Our new HemoSphere capital platform **strengthens our core** portfolio

We are **pioneering predictive analytics** to improve decision making for high risk surgical patients with the launch of Hypotension Prediction Indicator (HPI)

ClearSight continues to **expand penetration** into the Enhanced Surgical Recovery global opportunity

The leader in the \$765M global hemodynamic monitoring industry*

*Includes pulmonary artery catheters and pressure monitoring products.

Edwards Lifesciences

Health Care Trends Favor Hemodynamic Monitoring

Hospital Patient Monitoring Segments Growing at 3-5%

** Third party research and internal estimates*

Health Care Trends

- Hospitals caring for sicker patients
- Quality standards and outcomes
- Digital innovation and data analytics
- Less invasive solutions

12/7/17 3

Edwards Lifesciences

Broad Portfolio Leading Toward Noninvasive Solutions

~11M
patients
reached / year

~30K
monitors
installed

~600k
patients
reached / year

More invasive

Less invasive

Swan-Ganz
Pulmonary
Artery Catheters

Core Hemodynamic Products

~60% of revenue

TruWave
Transducers

Monitoring
Platforms

~10% of revenue

FloTrac
Sensors

ClearSight
Finger Cuffs


Enhanced Surgical Recovery Products

~30% of revenue

12/7/17 4

Edwards Lifesciences


HemoSphere Platform Builds a Foundation for the Future



**HemoSphere
All-in-One
Platform**


**Advanced
Swan-Ganz
Catheter**
VIGILANCE II
REPLACEMENT

PHASE I PLATFORM
2018




**FloTrac Sensor
Hypotension Prediction**
VIGILEO
REPLACEMENT

PHASE II PLATFORM
Next 6-12 months



**ClearSight Sensor
Assisted Fluid Management**
EV1000
REPLACEMENT

PHASE III PLATFORM
Next 12-24 months



Illustrative

**Next Generation
Capital Platform**

NEXT GEN PLATFORM

12/7/17 5

Edwards Lifesciences

Pioneering New Monitoring Categories to Advance Care

Increasing Clinical Value



**Monitoring platforms
and sensors**



**Descriptive
Monitoring**

Past

**Acumen Hypotension
Prediction Indicator**



**Predictive
Monitoring**

Present
Planned U.S. Launch in 2018

**Acumen Assisted
Fluid Management**



**Prescriptive
Monitoring**

Present
Planned FDA IDE in 2018

*Combination of
multiple systems*



**Semi-Closed-Loop
Systems**


Future

12/7/17 6

Breakthrough Predictive Analytics Integrated into HemoSphere May Expand to Lower Risk Procedures

Acumen Hypotension Prediction Indicator (HPI)


Alerts clinicians to address potentially developing low blood pressure events **before they occur**



As blood pressure decreases, mortality increases

1. EJ Mascha et al., Anesthesia. 2015; 104K patient study demonstrating increased mortality as Mean Arterial Pressure decreased from 80 to 50mmHg

ClearSight Noninvasive Solutions Expanding Enhanced Surgical Recovery to More Patients




ClearSight Finger Cuff

Enhanced Surgical Recovery (ESR) is focused on reducing complications and length of stay

>50 peer reviewed studies have shown that ESR improves outcomes


EV1000 Monitoring Platform

Improper fluid balance contributes to complications





1. Thacker et al. Perioperative Fluid Utilization Variability and Association With Outcomes. AnnSurg 2016

Underlying Global Sales Growth Outlook



Executive Summary



We are building upon our heritage of leadership to create the future with HemoSphere, predictive monitoring solutions and expanding ESR adoption with ClearSight

Critical Care products can benefit millions more patients per year